European Medicines Agency
Evaluation of Medicines for Human Use

11 June 2004
EMEA/CHMP/409/04

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
1-3 JUNE 2004 PLENARY MEETING
MONTHLY REPORT

The Committee for Medicinal Products for Human Use (CHMP) held its 1st plenary meeting from 1-3 June 2004. Thomas Lönngren, Executive Director of the EMEA, expressed his warm welcome to the members and alternates of the new Committee and chaired the meeting until the new Chairperson and Vice-Chairperson were elected. Dr Daniel Brasseur and Dr Eric Abadie were respectively elected Chairman and Vice-Chairman and were congratulated by the Executive Director.

Following the entry into force of parts of the new pharmaceutical legislation the CHMP replaces the Committee for Proprietary Medicinal Products (CPMP); it is composed of one member and one alternate per Member State in addition to one member and one alternate each from Iceland and Norway.

It is also the first time after the enlargement of the European Union on 1 May that members from the 10 new Member States are fully included in the Committee's work.

Product related issues

- The Committee adopted one positive opinion on the initial marketing authorisation application for **Apidra** (insulin glulisine) from Aventis Pharma Deutschland GmbH for the treatment of adult patients with diabetes mellitus. EMEA review began on 23 June 2003 and the opinion was adopted on 3 June 2004, with an active review time of 215 days.

  A summary of this opinion, including the full indication, is available on the EMEA web site: http://www.emea.eu.int.

- The Committee also gave a positive opinion on extending the therapeutic indication for **Aldara** (imiquimod) from Laboratories 3M Sante, to include adult patients with small superficial basal cell carcinoma. Aldara was first authorised in the European Union on 18 September 1998.

  Further information on this extension will be included in the public assessment report (EPAR) once the European Commission has granted final approval.

- The Committee also adopted 3 opinions (1 Part B and 2 Part A) for "line extension" applications (in accordance with Annex II of Commission Regulation (EC) No. 1085/2003).

An overview of centralised procedures since 1995 is given in **Annex 1**. The list of medicinal products for which marketing authorisations have been granted by the European Commission since the CPMP plenary meeting in April 2004 is provided in **Annex 2.** The post-authorisation centralised procedures finalised during this meeting are summarised in **Annex 3**.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.eu.int http://www.emea.eu.int

Non-product related issues

The CHMP was informed of the outcome of the discussions of the Scientific Advice Working Group (SAWG) meeting, which was held on 11-12 May 2004. For further details, please see **Annex 4**.

Documents prepared by the CHMP Working Parties and Ad Hoc Groups adopted during the 1-3 June 2004 CHMP meeting are listed in **Annex 5**. There was no Organisational Matters meeting (ORGAM). Therefore, in order to allow discussions on the documents prepared, the adoption of a number of documents was postponed to the next CHMP meeting.

Organisational Matters

As there was no ORGAM meeting, the plenary CHMP meeting began with discussions devoted to organisational matters, which included:

- Introduction of the new Committee by the EMEA Executive Director and presentation of the new CHMP members and alternates.
- Election of the Chairperson and the Vice-Chairperson of the Committee. Dr Daniel Brasseur and Dr Eric Abadie were respectively elected Chairman and Vice-Chairman of the CHMP. The members and alternates of the Committee are listed in **Annex 6**.
- Adoption of the CHMP Rules of Procedure in accordance with Title IV of the new Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. The Rules of Procedure will be forwarded to the European Commission and to the EMEA Management Board.
- Discussion on the need for Co-opted members. The Committee agreed to review the existing expertise of the Committee and to identify any complementary specific scientific competencies. Further to this review, the Committee will discuss the procedure for the appointment of Co-opted members and the number of Co-opted members required.
- Discussion on the timetable for the establishment of Working Parties, the Scientific Advice Working Party and Scientific Advisory Groups. The composition of these parties and groups will remain the same until the CHMP discuss their mandates and until the appointment of new members and the election of new Chairpersons/Vice-Chairpersons. The current Chairpersons will continue to chair the meetings until the election of new Chairpersons.

Upcoming meetings following the 01-03 June 2004 CHMP meeting:

- The 2nd CHMP plenary meeting of the CHMP will be held on 22-24 June 2004.
- The first CHMP ORGAM is scheduled to take place on 21 June 2004.

PROCEDURAL ANNOUNCEMENT

- **Additional meeting of the Scientific Advice Working Party**

An additional meeting of the Scientific Advice Working Party (SAWP) is planned on 3 August 2004. Companies willing to submit a request for Scientific Advice or Protocol Assistance for a start of the procedures at the August meeting should notify the EMEA (Scientificadvice@emea.eu.int) by 30 June 2004. The deadline for submitting the final requests is 19 July 2004.

- **Advisory note on dossier requirements**

Marketing Authorisation Holders and Applicants are advised that they should continue to follow the current dossier requirements for their initial Marketing Authorisation applications and Variation Applications for new clinical indications. A revised dossier requirements/contact information document will be published following the 22-24 June CHMP meeting.

Mutual Recognition procedure

The CHMP noted the report from the Mutual Recognition Facilitation Group (MRFG) meeting held on 24 May 2004. For further details, please see **Annex 7.**

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicines for Human Use, Tel. (+44-20) 74 18 85 92
This CHMP Monthly Report and other documents are available on the Internet at the following address:
http://www.emea.eu.int

EMEA CENTRALISED PROCEDURES

	1995 - 2000	2004	Overall Total
Scientific Advice	367	25	392
Follow-up to Scientific Advice	60	0	60
Protocol Assistance	30	13	43
Follow-up to Protocol Assistance	9	1	10

	1995-2003			2004			
	Part A	**Part B**	**Total**	**Part A**	**Part B**	**Total**	
Applications submitted	134	271	405	6	9	15	420
Consultation for Medical Device[1]	0	1	1	0	0	0	1
Withdrawals	22	55	77	0	3	3	80
Positive CPMP opinions[2]	99	172	271	4	8	12	283[3]
Negative CPMP opinions[4]	2	5	7	0	0	0	7[5]
Marketing authorisations granted by the Commission	91	164	255	3	9	12	267[6]

	1995-2003			2004			Overall Total
	Part A	**Part B**	**Total**	**Part A**	**Part B**	**Total**	
Variations type I	771	1505	2276	23	178	201	2477
Positive opinions, variations type II	583	697	1280	41	57	98	1378
Negative opinions, variations type II	1	6	7	0	0	0	7
Extensions (Annex II applications)	49	56	105	2	3	5	110

[1] Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivatives of human blood or plasma and Directive 2001/104/EC.
[2] 16 positive opinion corresponding to 16 Orphan Medicinal Products
[3] 283 positive opinions corresponding to 217 substances
[4] In case of appeal, the opinion will not be counted twice
[5] 7 negative opinions corresponding to 6 substances (2 of these negative opinions correspond to 2 Orphan Medicinal Products)
[6] 267 marketing authorisations corresponding to 202 substances

MEDICINAL PRODUCTS GRANTED A COMMUNITY MARKETING AUTHORISATION UNDER THE CENTRALISED PROCEDURE SINCE APRIL 2004 CPMP MONTHLY REPORT

Invented Name	Dukoral
INN	vibrio cholerae and recombinant cholera toxin B-subunit
Marketing Authorisation Holder	SBL Vaccin AB
ATC code	J07AE01
Indication	Active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas
CPMP Opinion date	24/07/2003

Invented Name	Litak
INN	cladribine
Marketing Authorisation Holder	Lipomed GmbH
ATC code	L01BB04
Indication	Treatment of non-Hodgkin's lymphoma
CPMP Opinion date	22/10/2003

Invented Name	Lysodren
INN	mitotane
Marketing Authorisation Holder	Laboratoire HRA Pharma
ATC code	L02BG
Indication	Treatment of adrenal cortical carcinoma
CPMP Opinion date	21/01/2004

Invented Name	Velcade
INN	bortezomib
Marketing Authorisation Holder	Millennium Pharmaceuticals Ltd
ATC code	L01XX
Indication	Treatment of patients with refractory multiple myeloma
CPMP Opinion date	21/01/2004

OUTCOME OF THE 1-3 JUNE 2004 CHMP MEETING IN RELATION TO CENTRALISED APPLICATIONS IN THE POST-AUTHORISATION PHASE

Opinions for Type II Variation applications	
Number of Opinions	**Outcome**
1 Extension of indication	1 Positive opinion
25 SPC changes	25 Positive opinions
12 Quality changes	12 Positive opinions

Opinions for Annual Re-Assessment applications		
Name of Medicinal Product (INN) **MAH**	**Outcome**	**Comments**
Carbaglu (carglumic acid) Orphan Europe SARL	Positive opinion	Marketing Authorisation will remain under exceptional circumstances
Trisenox (arsenic trioxide), Cell Therapeutics (UK) Ltd.	Positive opinion	Marketing Authorisation will remain under exceptional circumstances

Opinions for Renewal applications		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
Ziagen (abacavir), GlaxoSmithKline,	Positive opinion	---

OUTCOME OF THE 1-3 JUNE 2004 CHMP MEETING IN RELATION TO SCIENTIFIC ADVICE PROCEDURES

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharma ceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Chemical	Hypertension	X					X	X	
Biological	Neutropenia in patients treated with cytotoxic chemotherapy for malignancy	X						X	
Chemical	Type 2 diabetes	X					X	X	
Chemical	Glioma		X				X	X	
Biological	Cervical dystonia; Axillary hyperhidrosis	X				X	X	X	
Chemical	Aneurysmal subarachnoid haemorrhage		X				X	X	X
Chemical	Systemic secondary amyloidosis		X				X	X	X
Chemical	Avoidance/decrease of blood/red cells transfusion in patients undergoing surgery.	X						X	
Chemical	Colorectal cancer	X					X	X	

SA: Scientific Advice

PA: Protocol Assistance

The above-mentioned 6 Scientific Advice letters and 3 Protocol Assistance letters were adopted at the 1-3 June CHMP meeting.

The Committee accepted 10 Initial Scientific Advice Requests, 3 Follow-up Scientific Advice Requests and 3 Initial Protocol Assistance Requests.

DOCUMENTS PREPARED BY THE CHMP WORKING PARTIES AND AD HOC GROUPS ADOPTED DURING THE 1-3 JUNE CHMP MEETING

EFFICACY WORKING PARTY

Reference number	Document	Status
CHMP/EWP/1738/04	Recommendation on the need for revision of the CPMP Points to Consider on HRT	Adopted

LIST OF CHMP MEMBERS AND ALTERNATES

Member	Alternate	Nominating Member State
Eric ABADIE	Jean-Hugues TROUVIN	France
János BORVENDÉG	Ágnes GYURASICS	Hungary
Jens ERSBØLL	Steffen THIRSTRUP	Denmark
Jacqueline GENOUX-HAMES	Jean-Louis ROBERT	Luxembourg
Ian HUDSON	Julia DUNNE	United Kingdom
Arthur ISSEYEGH	Panayiota KOKKINOU	Cyprus
Raul KIIVET	Alar IRS	Estonia
Gottfried KREUTZ	Manfred HAASE	Germany
Beatriz SILVA LIMA	Cristina SAMPAIO	Portugal
Metoda LIPNIK-ŠTANGELJ	Barbara RAZINGER-MIHOVEC	Slovenia
David LYONS	Patrick SALMON	Ireland
Pieter NEELS	Bruno FLAMION	Belgium
Giuseppe NISTICÓ	Pasqualino ROSSI	Italy
Sif ORMARSDÓTTIR	Magnus JOHANNSSON	Iceland
Michał PIROŻYŃSKI	Piotr SIEDLECKI	Poland
Heribert PITTNER	Josef SUKO	Austria
Juris POKROTNIEKS	Indulis PURVINŠ	Latvia
Gonzalo Calvo ROJAS	Fernando de ANDRÉS- TRELLES	Spain
Tomas SALMONSON	Per NILSSON	Sweden
Eva SKOVLUND	Liv MATHIESEN	Norway
Pavel ŠVEC	Leila FARAH	Slovakia
Milan ŠMÍD	*(to be nominated)*	Czech Republic
Markku TOIVONEN	Pekka KURKI	Finland
Helen VELLA	Patricia Vella BONANNO	Malta
Romaldas MAČIULAITIS	Mykolas MAURICAS	Lithuania
Barbara van ZWIETEN-BOOT	Frits LEKKERKERKER	The Netherlands
Nikolaos DRAKOULIS	Michalis AVGERINOS	Greece

Report from the meeting held on 24 May 2004

General Issues

Documents: Simultaneous applications (Article 17 paragraph 2 of Directive 2001/83/EC) Member States Operating Procedure and Triggering of Mutual Recognition by Member States (Article 18 of Directive 2001/83/EC)

In view of the enlargement on 1 May 2004, an updated version of each document has been adopted by the group and is currently available on the website under the headings Application for MRP and General Information on the MRP, respectively.

MRFG Best Practice Guides for the Submission and Processing of Variations in the Mutual Recognition Procedure

An updated version of Chapter 5, to include information on the implementation of variations affecting the SPC, label and leaflet, has been adopted by the group and will be published on the website.

Implementation of the Commission Decision after a referral procedure

The SPC of the finalised referral for pravastatin has been published on the EMEA website (www.emea.eu.int/htms/human/referral/referral.htm) and the SPC of the recently finalised referral for simvastatin will also be published on the EMEA website.

Meeting schedule

The next MRFG meeting will be held on 21 June 2004.

Mutual Recognition Monitoring

Due to change in platform of the Eudratrack / CTS tracking sytem, statistics related to the monthly monitoring part of the press release will be available later in the month.

All documents mentioned in this press release can be found at the MRFG website at the European Medicines Authorities Windows under the heading MRFG Guidance.

Information on the above mentioned issues can be obtained from the presiding chair of the MRFG:

*Dr. Caitríona **FISHER***
Irish Medicines Board
The Earlsfort Centre
Earlsfort Terrace
Dublin 2 - IRELAND

Phone: + 353 1 676 4971
Fax: + 353 1 676 8490
e-mail: caitriona.fisher@imb.ie

*Or you could visit the **MRFG web site** at the EUROPEAN NATIONAL MEDICINES AUTHORITIES WINDOW:*
http://heads.medagencies.org/